Surgery plus cancer drugs for kidney cancer that spread
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to join and follow all trial rules, and be able to attend visits and tests.
- You are age 18 or older, and have kidney cancer that has already spread (confirmed by a biopsy).
- Your cancer is “synchronous metastatic,” meaning the kidney primary tumor is still in place.
- Your cancer must be measurable on scans and your overall health should be good enough (Karnofsky score 70 or higher).
- Your blood, liver, and kidney tests must be within required ranges.
- You must not have had prior drug treatment for this metastatic kidney cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
This trial is for people with kidney cancer that has spread to other parts of the body, who still have their original kidney tumor. If your cancer has responded very well to immunotherapy (a type of treatment that helps your immune system fight cancer), doctors want to see if removing the kidney tumor now can improve your outcome.
This trial tests whether removing or burning (ablating) the main kidney tumor helps people with advanced kidney cancer who are already doing well on immunotherapy. Researchers want to see if combining local treatment with ongoing immunotherapy can improve outcomes.
This study looks at whether people with metastatic kidney cancer can be managed with standard immune-based treatment and then have their main kidney tumor removed. It is meant for people who can have surgery and whose cancer has not grown at the time this approach is considered.
This trial tests whether starting immunotherapy (a type of medicine that helps your immune system fight cancer) right away, and delaying surgery to remove the kidney tumor, is a safe and effective approach for people with advanced kidney cancer that has spread. It may help you avoid or delay surgery while still controlling the cancer.
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
Hear when a new Kidney Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.